Q-omics provides the consensus-scored SPATA5 profile across patient tissues and cancer cell-line models. SPATA5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SPATA5 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SPATA5 RNA expression shows 21,317 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where SPATA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA5 survival associations across molecular data types. SPATA5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA5 RNA expression–survival associations across cancer types. High SPATA5 expression shows unfavorable associations in MESO, LIHC, ACC, LUAD and PAAD, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for SPATA5 RNA expression.
This table summarizes SPATA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPATA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA5 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, STAD and CHOL. The HNSC box plot shows higher SPATA5 RNA expression in tumor versus normal tissue (log2 FC = +0.845, t-test p < 0.001).
This table shows molecular features associated with SPATA5 in patient tissues and cancer cell lines. In patient samples, SPATA5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
